Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LeAD: Levetiracetam in Early Alzheimer's Disease
NCT03875638Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Aug 2019
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levetiracetam in Alzheimer's disease (AD) (4 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Neuropsychological Test Battery at 5 months, Transcranial magnetic stimulation resting motor threshold at 5 months and 6 more. Started Aug 2019; status: completed.
02
Drugs
levetiracetam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03875638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875638.